Pinned Tweet
If you want to grow your home dialysis program then do urgent start PD. Check out the @RPANephrology white paper out on doing just this. Retweet to your fellow nephs.
renalmd.org/store/ViewProduc…
Harry Giles retweeted
Higher urine protein-to-creatinine ratio was strongly associated with faster CKD progression and earlier kidney failure in >2,700 adults with advanced CKD. These findings in #ASNCJASN highlight the value of a simple test for risk stratification in clinical practice. kidney.pub/CJASN1206
Harry Giles retweeted
Many don't remember when Amgen and J & J captured nephrology's guidelines in the early 2000s to promote unsafe hemoglobin targets. Dr Coyne, rang the bell, and told the world. Few wanted to hear him. Many hated him for it. But Dan was on the right side of history
ajkdblog.org/2016/04/03/neph…
Harry Giles retweeted
Replying to @kidney_boy @brian_rifkin
Fully agree. This “redefinition “ of AKI is long overdue. While you are at it, a redefinition” of CKD using age- adapted eGFR thresholds is also long overdue,
Harry Giles retweeted
In this @GoHealio interview, a cardiologist and nephrologist discuss:
⭐ Why the first cardiovascular-kidney-metabolic guideline was established
⭐ How specialists can collaborate to improve patient outcomes
Read along 👇
vist.ly/5ff3h
Harry Giles retweeted
⚠️We finally have a cure for Guillain-Barre syndrome.
Tanruprubart switches off the disease process by day 4 after a single infusion, no prolonged ICU stays, no chronic disability.
Truly a game changer drug.
Hopefully coming to an ICU near you in 2027.
ir.annexonbio.com/node/11196…
We have a new and exciting treatment for Guillain Barre Syndrome (#GBS).
ANX005 (Tanruprubart) has the potential to reverse #GBS with a single injection.
The FORWARD (GBS-05) trial is currently randomising in the US.
It works in Bangladesh, we’ll know this year whether it works in America and Europe, no reason to think it won’t.
Months of ventilation and lifelong disability finally have an effective therapy.
I’ve reviewed the data previously.
xitter.cf/richardhirschs1/status…
Harry Giles retweeted
A forceful critique of the USPSTF, authored by the president of @KidneyPatients. I, for one, could only tepidly endorse CKD screening before the CREDENCE trial, but conditions have changed a lot this decade.
washingtonexaminer.com/op-ed…
Harry Giles retweeted
Those with severe SHPT who are transplant candidates are best managed by parathyroidectomy pre-transplant. This leads to the greatest improvement in BMD, a remarkable improvement in QoL, and precludes development of hyperpara and hypercalcemia after Tpt. nephsap.org/view/journals/ne…
A 10-year Brazilian study in #ASNKidney360 found persistent hyperparathyroidism after kidney transplantation is common and linked to a 2.3x higher risk of poor graft function. KTX should not be viewed as a definitive treatment for severe secondary HPT. #KidneyTransplant kidney.pub/KID1233?utm_sourc…
Harry Giles retweeted
My wife and I own Forest Park Pharmacy, and we don't accept insurance. None of it. That decision is exactly why we could fix what happened to a patient today.
A family came in wanting to transfer their kid's antibiotic to us. The child had already STARTED the course. Then, mid-treatment, the insurance company decided the last 14 tablets suddenly needed a "prior authorization" before the other pharmacy could hand them over. A sick kid, halfway through an antibiotic, and the answer was "please hold."
The drug is linezolid. It's a generic. It's been generic for over a decade. It treats serious gram-positive infections — the kind you do NOT want to stop antibiotics in the middle of, because an interrupted course is how you breed resistant bugs and end up right back where you started.
So why the hold-up on a cheap, common generic? Follow the fake math.
Insurance and the PBMs behind them price drugs off a number called AWP — "Average Wholesale Price." People in my industry have another name for it: "Ain't What's Paid." It's a benchmark number, not a real-world cost. On paper, the AWP for just those last 14 tablets is about $2,500.
My cash price for the same 14 tablets? $18.
Read that again. The system that's supposedly "protecting" this family from cost is the same system that inflated an $18 medication into a $2,500 line item, then slapped a prior auth on it to "review the expense" THEY invented. They manufactured the problem, then billed everyone for the privilege of solving it — and made a sick kid wait while they did it.
This is the whole game. When a drug is priced honestly, there's nothing to "manage." When it's priced off a fantasy benchmark, you get spread pricing, PA paperwork, pharmacy phone trees, and delayed treatment — all dressed up as cost control.
Here's the part nobody tells you: roughly 90% of prescriptions are low-cost generics. For the vast majority of what people pick up every day, running it through insurance does two things — raises the real cost and risks delaying your care. That's it. That's the value-add.
That's why we fired the insurance companies. No middleman deciding your kid can't finish their antibiotics on schedule. No fake prices. Just the real number, on the shelf, today.
The medication was always cheap. The insurance was the expensive part.
Harry Giles retweeted
Every healthcare headline is now the same story:
Government underpays.
Hospitals overcharge.
Insurers deny.
Employers absorb.
Patients finance.
Physicians get blamed.
And somehow the solution is always giving more power to the people who built the maze.
Harry Giles retweeted
THIS IS THE BEST PAPER OF 2026 SO FAR, A MONUMENTAL BREAKTHROUGH, A REVOLUTION IN THE FIELD OF INFLAMMATORY CONDITIONS:
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…
Harry Giles retweeted
Call from transplant nephrologist,’ your dialysis patient received a transplant this morning’
Harry Giles retweeted
If you are not blown away by the power of OpenEvidence AI then you are not using it correctly.
I recently tried some pretty complex cases and it provided a perfect differential, next diagnostic steps, areas of uncertainty, and follow up plan.
Harry Giles retweeted
UAB has joined the National Kidney Registry and completed its first transplant through the network in February. Shikha Mehta, MD, @UAB_NRTC and colleagues share how this partnership improves matching, outcomes, donor protections, and access to living donor transplantation.
Harry Giles retweeted
At Kaiser Permanente Northern California, we evaluated more than 3000 PD catheter placements using the image-guided percutaneous (IGP) technique versus the advanced laparoscopic surgical (ALS) technique. It turns out IR placement not only delivers excellent outcomes (matching or surpassing surgical technique) but is also patient-friendly (flexible scheduling, no full anesthesia) and involves much lower resource utilization.
academic.oup.com/ckj/advance…
Harry Giles retweeted
The journey begins.
globenewswire.com/news-relea…
Harry Giles retweeted
Roughly 38% of all kidney discards can be attributed to “overcalling” or misinterpretation of kidney biopsy results.
This is why we will be sharing more content in the coming weeks about how to read and interpret donor biopsies. In the meantime, head to organdonationalliance.org to learn more about #NationalDonorDay. #ckd































